At this time, it is not possible to purchase a generic version of Alvesco (ciclesonide inhaler). The brand-name medication is currently protected by patents that prohibit any generic forms of the drug from being sold in the United States. The earliest predictable date that a generic version could become available is October 2017, when the drug's first patent expires.
Alvesco® (ciclesonide inhaler) is a prescription medication approved for the treatment of asthma. It is an inhaled corticosteroid (also known as an inhaled steroid) that is taken twice a day to prevent asthma attacks.
Alvesco is made by Sepracor, Inc. Currently, this medication is protected by patents that prevent any generic versions from being sold in the United States.
The first patent for Alvesco currently expires in October 2017. This is the earliest predictable date that a generic version of Alvesco could become available. However, other circumstances could come up to extend or shorten this exclusivity period, such as lawsuits or other patents for specific Alvesco uses.
Once the patent expires, several companies may begin manufacturing a generic Alvesco drug.
No -- ciclesonide is the active ingredient in Alvesco (as well as in Omnaris™, a nasal spray), but is not a generic version of it. What can be confusing is that oftentimes, the active ingredient of any drug is referred to as the "generic name." The generic name is different from a generic version of a medicine.
In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.